Abstract Details

Title Are Elevated Interleukin-6 Serum Levels Associated with Increased Encephalopathy and In-hospital Mortality rates in SARS-CoV2 Patients

Topic Infectious Disease

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 4-001

Objective To identify whether elevated serum IL-6 levels are associated with increased occurrence of encephalopathy in hospitalized patients with SARS-CoV-2 infection.

Background SARS-CoV-2 induced cytokine storm may cause encephalopathy, which has been associated with poor prognosis.

Design/Methods IL-6 was measured in 201 PCR-confirmed COVID-19 patients who were hospitalized between Mar 1st and Apr 30th, 2020. Patients who did or did not develop encephalopathy with 24 hours after IL-6 collection were identified as encephalopathy and control group respectively. The Rest group included patients who developed encephalopathy during their hospitalization more than 24 hours after IL-6 collection. Mann-Whitney and non-paired t-test were used to compare demographics, outcomes, and IL-6 distribution.

Results 78, 85 and 38 encephalopathy, control and rest patients were identified respectively. The mean age, mean IL-6 level, in hospital mortality and comorbid conditions were significantly higher in the encephalopathy group compared to the control group (63.7 vs 54.8 year; 96.7 pg/mL vs 68.5 pg/mL; 53%vs 1%; 73.1% vs 43.5% p<0.01). The need for invasive ventilation, acute respiratory distress syndrome, acute renal failure and multiorgan failure was significantly higher in the encephalopathy compared to the control group (56% vs 1%; 68%vs 20%; 52% vs 17%; 86% vs 45.2% p<0.01). There was no significant difference in serum IL-6 distribution or mortality between the encephalopathy and rest group.

Conclusions Encephalopathy in patients with SARS-CoV2 infection is associated with significantly higher in-hospital mortality, serum IL-6 levels, comorbid conditions, and respiratory and multiorgan failure. The distribution of serum IL-6 concentration and mortality were not different between the encephalopathy group, and the rest group. Work is in progress to investigate whether IL-6 level can predict the occurrence of encephalopathy in patients hospitalized with SARS-CoV2 and whether the combination of encephalopathy and serum IL-6 level is a better predictor for in-hospital mortality than each of the markers alone.

Authors/Disclosures
Pratibha Surathi, MD (Rutgers New Jersey Medical School) PRESENTER	Dr. Surathi has nothing to disclose.
Sviatoslav Redko, MD	Dr. Redko has nothing to disclose.
Toluwalase O. Tofade, MBBS (Medstar)	Dr. Tofade has nothing to disclose.
Evan Huff, MD	Mr. Huff has nothing to disclose.
Mustafa Jaffry	Mr. Jaffry has nothing to disclose.
Kranthi K. Mandava	Mr. Mandava has nothing to disclose.
Jeffrey M. Kornitzer, MD, FAAN (New Jersey Pediatric Neuroscience Institute (NJPNI))	Dr. Kornitzer has nothing to disclose.
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��